| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Fedratinib | Fedratinib FDR Impuity 2 | VE007860 | View |
| Fedratinib | Fedratinib FDR Impurity 1 | VE007859 | View |
| Fedratinib | Fedratinib FDR Impurity 3 | VE007861 | View |
| Catalogue No. | VE007860 |
| CAS No. | N/A |
| Molecular Formula | C15H20Cl2N4O2S |
| Molecular Weight | 391.32 g/mol |
| Parent drug | Fedratinib |
| IUPAC Name | N-(tert-butyl)-3-((2-chloro-5-methylpyrimidin-4-yl)amino)benzenesulfonamide hydrochloride |
| Synonyms | N/A |
| References | “Sci-Hub, Safety and Efficacy of Fedratinib in Patients with Primary or Secondary Myelofibrosis. JAMA Oncology, 1(5), 643, 10.1001/Jamaoncol.2015.1590.” Sci-Hub.se, 2015, sci-hub.se/jamanetwork.com/journals/jamaoncology/article-abstract/2330618. |
| Status | In-stock |
| ListName | Fedratinib FDR Impuity 2 |
| Exclusively Supplied by Veeprho | Exclusively Supplied by Veeprho |
"*" indicates required fields
